

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Meihao Medical Group Co., Ltd
美皓醫療集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1947)

**(1) CHANGE OF COMPANY SECRETARY,
AUTHORISED REPRESENTATIVE AND PROCESS AGENT
AND**

(2) CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG

**CHANGE OF COMPANY SECRETARY, AUTHORISED REPRESENTATIVE AND
PROCESS AGENT**

The board of directors (the “**Board**”) of Meihao Medical Group Co., Ltd (the “**Company**”) hereby announces that Mr. Lee Chung Shing (“**Mr. Lee**”) has tendered his resignation as the company secretary of the Company (the “**Company Secretary**”), the authorised representative of the Company (the “**Authorised Representative**”) pursuant to Rule 3.05 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”), and the agent for acceptance of service of process and notices on behalf of the Company in Hong Kong (the “**Process Agent**”) under Rule 19.05(2) of the Listing Rules and Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong), with effect from 31 March 2024 due to other work arrangements.

Mr. Lee has confirmed that he has no disagreement with the Board and there is no matter relating to his resignation that needs to be brought to the attention of the Stock Exchange or the shareholders of the Company.

Following the resignation of Mr. Lee, the Board is pleased to announce that, Ms. Chan Yuk Wing (“**Ms. Chan**”) has been appointed as the Company Secretary, the Authorised Representative and the Process Agent of the Company with effect from 31 March 2024.

The biographical details of Ms. Chan are set out below:

Ms. Chan is currently a director of a company which is regulated by the Registry for Trust and Company Service Providers of Hong Kong. Ms. Chan possesses extensive experience in the provision of corporate services and compliance services to a number of companies listed on the Stock Exchange. Ms. Chan is familiar with the Listing Rules, the Companies Ordinance as well as compliance work for offshore companies. Ms. Chan is a Chartered Secretary, a Chartered Governance Professional and an Associate of both The Hong Kong Chartered Governance Institute (formerly known as The Hong Kong Institute of Chartered Secretaries) and The Chartered Governance Institute (formerly known as The Institute of Chartered Secretaries and Administrators). Ms. Chan is a master degree holder of Corporate Governance awarded by Hong Kong Metropolitan University in 2021. Ms. Chan possesses the qualifications of a company secretary as required under Rule 3.28 of the Listing Rules.

The Board would like to take this opportunity to express its sincere gratitude to Mr. Lee for his valuable contributions to the Company during his tenure of office and welcome Ms. Chan on her new appointment.

CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG

The Board further announces that the principal place of business of the Company in Hong Kong will be changed to Unit 11, 5/F, Bedford Factory Building, No. 51 Bedford Road, Tai Kwok Tsui, Kowloon, Hong Kong with effect from 31 March 2024.

By order of the Board
Meihao Medical Group Co., Ltd
Wang Xiaomin
Chairman and Executive Director

Hong Kong, 28 March 2024

As at the date of this announcement, the Board of the Company includes the executive Directors Mr. Wang Xiaomin and Ms. Zheng Man; and the independent non-executive Directors Mr. Ng Ming Chee, Ms. Tam Hon Shan Celia and Dr. Zhou Jian.